Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CRISPR-TILs |
Synonyms | |
Therapy Description |
CRISPR-TILs are autologous tumor infiltrating lymphocytes engineered to knockout PD-1 (PDCD1), which potentially induce tumor cell cytotoxicity (PMID: 35141398). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CRISPR-TILs | CRISPR-TILs are autologous tumor infiltrating lymphocytes engineered to knockout PD-1 (PDCD1), which potentially induce tumor cell cytotoxicity (PMID: 35141398). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06783270 | Phase I | CRISPR-TILs | T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma (CRISPR-TIL) | Recruiting | DNK | 0 |